Manuel Morgado
Overview
Explore the profile of Manuel Morgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
463
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Placido A, Azevedo D, Herdeiro M, Morgado M, Roque F
Epidemiologia (Basel)
. 2025 Jan;
6(1.
PMID: 39846531
Irisin is a protein resulting from a proteolytic cleavage of fibronectin type III domain-containing protein 5 (FND5). The ability of irisin to modulate adipocyte and control glucose metabolism in human...
2.
Lopes A, Lourenco O, Morgado M
Expert Rev Clin Pharmacol
. 2024 Oct;
17(11):1081-1088.
PMID: 39450504
Background: We aimed to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with type 2 diabetes mellitus (T2DM) in clinical practice....
3.
Lopes A, Lourenco O, Morgado S, Gaspar A, Freire I, Eusebio I, et al.
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675382
Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), has shown demonstrated benefits for renal and cardiovascular outcomes in large clinical trials. However, short-term concerns regarding its impact on renal function and...
4.
Martins V, Jesus M, Pereira L, Monteiro C, Duarte A, Morgado M
Pharmaceuticals (Basel)
. 2023 Oct;
16(10).
PMID: 37895811
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer....
5.
Jesus M, Cabral A, Monteiro C, Duarte A, Morgado M
Curr Oncol
. 2023 Jul;
30(7):6533-6545.
PMID: 37504339
Poly (ADP-Ribose) polymerase inhibitors (PARPi) have emerged as a targeted therapy in cancer treatment with promising results in various types of cancer. This work aims to investigate the profile of...
6.
Carvalho da Silva S, Jesus M, Roque F, Herdeiro M, Costa E Sousa R, Duarte A, et al.
Curr Oncol
. 2023 May;
30(4):4139-4152.
PMID: 37185428
Adverse drug reactions (ADRs) are responsible for almost 5% of hospital admissions, making it necessary to implement different pharmacovigilance strategies. The additional monitoring (AM) concept has been highlighted and intended...
7.
Lopes A, Lourenco O, Roque F, Morgado M
Biomedicines
. 2023 Feb;
11(2).
PMID: 36830792
Type 2 diabetes mellitus (T2DM) is closely associated with other pathologies, which may require complex therapeutic approaches. We aim to characterize the clinical and pharmacological profile of T2DM patients admitted...
8.
Lopes A, Roque F, Lourenco O, Herdeiro M, Morgado M
Expert Opin Drug Saf
. 2023 Jan;
22(6):455-461.
PMID: 36695099
Background: Semaglutide is a Glucagon-like peptide-1 receptor agonist used in the second-line treatment of poorly controlled type 2 diabetes and can be used in monotherapy or associated with other oral...
9.
Tavares A, Placido A, Rodrigues D, Morgado M, Figueiras A, Herdeiro M, et al.
Healthcare (Basel)
. 2022 Jul;
10(7).
PMID: 35885868
(1) Background: According to the World Health Organization (WHO), benzodiazepines (BZD) are considered essential medicines for the treatment of several mental disorders in older adults over 65 years old. However,...
10.
Lopes A, Roque F, Morgado S, Dinis C, Herdeiro M, Morgado M
Behav Sci (Basel)
. 2021 Nov;
11(11).
PMID: 34821614
Type 2 diabetes mellitus is one of the main chronic diseases worldwide, with a significant impact on public health. Behavioral changes are an important step in disease prevention and management,...